Save time and get answers to complex questions with AI chat
Alogliptin benzoate cost?When will latisse patent expire?Is clarinex off patent?Quartette side effects?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?
See the DrugPatentWatch profile for sumatriptan
No. Sumatriptan is not a CGRP (calcitonin gene–related peptide) drug. It is a triptan (a serotonin 5-HT1B/1D receptor agonist) used for acute migraine treatment, not a CGRP-targeting therapy.
CGRP medicines block the CGRP pathway (for example, by targeting CGRP itself or its receptor), which can reduce migraine signaling. Sumatriptan works differently by activating serotonin receptors involved in cranial blood vessel and pain pathways.
CGRP therapies include monoclonal antibodies (like those that target CGRP ligand or the CGRP receptor) and CGRP antagonists (gepants). Sumatriptan is in the triptan class, so it does not fall into those categories.
It’s a common mix-up because many migraine treatments are discussed together. But sumatriptan’s mechanism and drug class are distinct from CGRP therapies. Sources: none provided.
Other Questions About Sumatriptan :